Alunbrig OverviewBrigatinib (INN, previously known as AP26113) is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc. Brigatinib has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). ARIAD has begun a Phase 1/2 clinical trial of brigatinib based on cancer patients' molecular diagnoses in September 2011. ALK was first identified as a chromosomal rearrangement in anaplastic lar...
Read more Alunbrig Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Brigatinib
Recent Alunbrig Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 30mg, 90mg
NDC Database Records for Alunbrig: (1 result)Sorted by National Drug Code
- 76189-113 Alunbrig 30 mg Oral Tablet, Coated by Ariad Pharmaceuticals Inc.